

Appointment of Joint Company Secretary

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) advises that it has appointed Ms Liesl Ellies as Joint Company Secretary, effective immediately.

Ms Ellies holds a Bachelor of Laws and a Bachelor of Asian Studies (Japanese) and is an experienced corporate lawyer having advised public and private companies across a wide range of industries on all aspects of corporate compliance, equity capital markets and mergers & acquisitions.

Following Ms Ellies’ appointment, Ms Ellies, Mr Nicholas Allan, and Mr Mitchell Wells will be joint Company Secretaries and will share responsibility for communications with ASX in relation to Listing Rule matters under ASX Listing Rule 12.6.

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

About Resonance Health

Resonance Health is an Australian healthcare technology and services company, specialising in the development and delivery of non-invasive medical imaging software and services.

The Company’s products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high quality quantitative measurements essential in the diagnosis and management of diseases.

Resonance Health’s dedication to scientific rigour and quality management has enabled it to achieve regulatory clearances for a range of Software as a Medical Device (**SaMD**) products in the USA, Europe and Australia and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Some of the SaMD products incorporate the use of Artificial Intelligence (**AI**):

- **FerriScan**® a core-lab product that provides accurate measurement of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart**® an AI-driven, non-invasive MRI-based device for the automated real-time measurement of LIC in patients.
- **HepaFat-AI**® an AI-driven, non-invasive MRI-based device for the automated real-time multi-metric measurement of liver fat in patients, for use in the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart**® an AI-driven, non-invasive MRI-based multi-parametric device that combines FerriSmart® and HepaFat-AI® into a consolidated report that provides accurate measurement of liver iron concentration and liver fat.

- **CardiacT2*** the most widely accepted MRI-based method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* has regulatory clearance from the TGA and CE marking.

The Company has an active development pipeline of additional medical imaging analysis products and services, including, **LungSmart**® and **Alert-PE**™; AI tools for the automated review of chest CT scans of patients with cystic fibrosis and suspected pulmonary embolism, respectively.

Stakeholders including clinicians and patients are encouraged to follow Resonance Health on Facebook, LinkedIn, and Twitter.

FOLLOW US



[/Resonance-Health-Ltd](#)



[/ResonanceHealth](#)



[/ResonanceHealthLtd](#)